Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


GREY:CLAZF - Post by User

Post by HighSkies2019on Oct 03, 2020 12:29pm
349 Views
Post# 31663012

Barely Hanging !!!

Barely Hanging !!!The more I read it...the more annoyed I get .. both Farrow and Salzman are questionable moving forward with their truths ... that being said I still believe in the NO R107 itself .. I can only hope they have more news to offer.. the only way I can see this moving forward is if there is a sale on the GVHD ...and sufficient enough profit to pay off talent and run phase 1 or partial and PP ....this is where Bob and Sal need to have an awesome NR to attract new investors... and hopes of great success to obtain the Barda and HHS funding .... it also says they already gave Sal a partial payment for R107..and in other NR had said that they were also moving the R107 along ... this gave me pause along with other things because would this not have to have a vote from shareholders first ....and if Bob has nothing of value interest when we go unhalted ...could be a very lonely ship......glta
<< Previous
Bullboard Posts
Next >>